Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals

References

• TeramotoTSasakiJUeshimaHExecutive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for JapaneseJ Atheroscler Thromb2007142455017485887
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNNational Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart AssociationImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation20041102227239Erratum in: Circulation 2004;110(6):763.15249516
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur J Cardiovasc Prev Rehabil200714Suppl 2S1S11317726407
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• BrugtsJJYetginTHoeksSEThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ2009338b237619567909
   PubMed Web of Science ®Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol200596455656316098311
   PubMed Web of Science ®Google Scholar
• TeramotoTKashiwagiAMabuchiHStatus of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan atherosclerosis society guideline for diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan lipid assessment program (J-LAP)Curr Ther Res Clin Exp20056628095
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCTreating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• DembowskiEDavidsonMHA review of lipid management in primary and secondary preventionJ Cardiopulm Rehabil Prev200929121219158581
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSINTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• McClureDLValuckRJGlanzMStatin and statinfibrate use was significantly associated with increased myositis risk in a managed care populationJ Clin Epidemiol200760881281817606177
   PubMed Web of Science ®Google Scholar
• YamazakiHFujinoHKanazawaMPharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet®). [In Japanese]Folia Pharmacol Jpn2004123349362
   PubMedGoogle Scholar
• AokiTNishimuraHNakagawaSPharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductaseArzneimittelforschung19974789049099296275
   PubMed Web of Science ®Google Scholar
• MorikawaSUmetaniMNakagawaSRelative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cellsJ Atheroscler Thromb20007313814411480454
   PubMedGoogle Scholar
• SuzukiHAokiTTamakiTHypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigsAtherosclerosis1999146225927010532682
   PubMed Web of Science ®Google Scholar
• MaejimaTYamazakiHAokiTEffect of pitavastatin on apolipoprotein A-I production in HepG2 cellBiochem Biophys Res Commun2004324283583915474503
   PubMed Web of Science ®Google Scholar
• RossRAtherosclerosis–an inflammatory diseaseN Engl J Med199934021151269887164
   PubMed Web of Science ®Google Scholar
• TakemotoMLiaoJKPleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsArterioscler Thromb Vasc Biol200121111712171911701455
   PubMed Web of Science ®Google Scholar
• SuzukiHKobayashiHSatoFPlaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbitsJ Atheroscler Thromb200310210911612740485
   PubMedGoogle Scholar
• KibayashiEUrakazeMKobashiCInhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cellsClin Sci (Lond)2005108651552115701058
   PubMed Web of Science ®Google Scholar
• HiraokaMNittaNNagaiMMCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathwayLife Sci200475111333134115234191
   PubMed Web of Science ®Google Scholar
• MorikawaSTakabeWMatakiCThe effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cellsJ Atheroscler Thromb20029417818312226549
   PubMedGoogle Scholar
• MarkleRAHanJSummersBDPitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cellsJ Cell Biochem2003901233212938153
   PubMed Web of Science ®Google Scholar
• MasamuraKOidaKKaneharaHPitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho familyArterioscler Thromb Vasc Biol200323351251712615662
   PubMed Web of Science ®Google Scholar
• NakanoKEgashiraKPitavastatin has most potent pro-healing effects on endothelial cells and inhibitory effects on proliferation of vascular smooth muscle cells-a potential treatment strategy for drug-eluting stentsThe 41st Annual Scientific Meeting of the Japan Atherosclerosis Society (July, 2009) general presentation No. 21.
   Google Scholar
• MorikawaSTakabeWMatakiCGlobal analysis of RNA expression profile in human vascular cells treated with statinsJ Atheroscler Thromb2004112627215153665
   PubMedGoogle Scholar
• InoueKSugiyamaAReidPCEstablishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectorisArterioscler Thromb Vasc Biol200727116116717095712
   PubMed Web of Science ®Google Scholar
• InoueIItohFAoyagiSFibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaBBiochem Biophys Res Commun2002290113113911779144
   PubMed Web of Science ®Google Scholar
• SagaraNKawajiTTakanoAEffect of pitavastatin on experimental choroidal neovascularization in ratsExp Eye Res20078461074108017418120
   PubMed Web of Science ®Google Scholar
• KohnoMShinomiyaKAbeSInhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatinHypertens Res200225227928512047044
   PubMed Web of Science ®Google Scholar
• HanJZhouXYokoyamaTPitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36Circulation200410979079614970117
   PubMed Web of Science ®Google Scholar
• KawakamiATaniMChibaTPitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanismArterioscler Thromb Vasc Biol200525242442915591219
   PubMed Web of Science ®Google Scholar
• HiraokaMYoshidaMA novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK1/2-dependent but not STAT3-dependent signaling transductionCirc J200367Suppl 1271
   Google Scholar
• ChinenIShimabukuroMYamakawaKVascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty ratsEndocrinology2007148116016517023526
   PubMed Web of Science ®Google Scholar
• OtaKSuehiroTAriiKEffect of pitavastatin on transactivation of human serum paraoxonase 1 geneMetabolism200554214215015690306
   PubMed Web of Science ®Google Scholar
• KimataHFujinoHKoideTStudies on the metabolic fate of NK-104, a new Inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in ratsDrug Metab Pharmacokinet1998135484498
   Google Scholar
• FujinoHYamadaIShimadaSMetabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonizationXenobiotica2003331274112519692
   PubMed Web of Science ®Google Scholar
• FujinoHSaitoTTsunenariYMetabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitorsXenobiotica20043411–1296197115801541
   PubMed Web of Science ®Google Scholar
• MukhtarRYReidJRecklessJPPitavastatinInt J Clin Pract200559223925215854203
   PubMed Web of Science ®Google Scholar
• FujinoHYamadaIKojimaJStudies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase. (5). In vitro metabolism and plasma protein binding in animals and humansXenobio Metabol Dispos1999146415424
   Google Scholar
• NakayaNTatenoMNakamuraTPharmacokinetics of reported dose NK-104 (pitavastatin) in healthy elderly and non-elderly volunteers [in Japanese]J Clin Therap Med2001176957970
   Google Scholar
• AndoHTsuruokaSYanagiharaHEffects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatinBr J Clin Pharmacol200560549449716236039
   PubMed Web of Science ®Google Scholar
• SakaedaTFujinoHKomotoCEffects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transportPharm Res200623350651216388406
   PubMed Web of Science ®Google Scholar
• HiranoMMaedaKShitaraYContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humansJ Pharmacol Exp Ther2004311113914615159445
   PubMed Web of Science ®Google Scholar
• HasunumaTNakamuraMYajiTThe drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine [in Japanese]J Clin Therap Med2003194381389
   Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid-lowering drugs: mechanisms and clinical relevanceClin Pharmacol Ther200680656558117178259
   PubMed Web of Science ®Google Scholar
• FujinoHYamadaIShimadaSMetabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase–effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in miceDrug Metab Pharmacokinet200217544945615618696
   PubMedGoogle Scholar
• HuiCKCheungBMLauGKPharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosisBr J Clin Pharmacol200559329129715752374
   PubMed Web of Science ®Google Scholar
• NakayaNTatenoMNakamuraTPharmacokinetics of repeated dose NK-104 (pitavastatin) in healthy elderly and non-elderly volunteers [in Japanese]J Clin Therap Med2001176957970
   Google Scholar
• JacobsonTAThe safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?Mayo Clin Proc20068191225123116970219
   PubMed Web of Science ®Google Scholar
• HayashiTYokoteKSaitoYPitavastatin: efficacy and safety in intensive lipid loweringExpert Opin Pharmacother2007108142315232717927486
   PubMed Web of Science ®Google Scholar
• SaitoYTeramotoTYamadaNClinical Efficacy of NK-104 (Pitavastatin), a New Synthetic HMG-CoA Reductase inhibitor, in the Dose Finding, Double Blind, Three-group Comparative Study [in Japanese]J Clin Therap Med2001176829855
   Google Scholar
• SaitoYYamadaNTeramotoTA randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemiaAtherosclerosis2002162237337911996957
   PubMed Web of Science ®Google Scholar
• NakayaNSaitoYMorisakiNPhase II Clinical Study of NK-104 (Pitavastatin) in Patients with Hyperlipidemia [in Japanese]J Clin Therap Med2001176789806
   Google Scholar
• ParkSKangHJRimSJA randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemiaClin Ther20052771074108216154486
   PubMed Web of Science ®Google Scholar
• BudinskiDArnesonVHounslowNPitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemiaClinical Lipidology200943291302
   Web of Science ®Google Scholar
• OseLBudinskiDHounslowNComparison of Pitavastatin to Simvastatin in Primary Hypercholesterolemia or Combined DyslipidemiaCurr Med Res Opin2009In press.
   PubMedGoogle Scholar
• KajinamiKKoizumiJUedaKEffects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study GroupAm J Cardiol200085217818310955373
   PubMed Web of Science ®Google Scholar
• OlssonAGIstadHLuurilaORosuvastatin Investigators GroupEffects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAm Heart J200214461044105112486429
   PubMed Web of Science ®Google Scholar
• TeramotoTSaitoYYamadaNClinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia – results of a multicenter long-term study. [in Japanese]J Clin Therap Med2001176885913
   Google Scholar
• FukutomiTTakedaYSuzukiSHigh density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitorInt J Cardiol200910[Epub Jan 12 2009].
   Google Scholar
• KawanoMNagasakaSYagyuHPitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patientsJ Atheroscler Thromb2008151414618270457
   PubMed Web of Science ®Google Scholar
• SasakiJIkedaYKuribayashiTA 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intoleranceClin Ther200830610891010118640465
   PubMed Web of Science ®Google Scholar
• YokoteKBujoHHanaokaHMulticenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hyper-cholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)Atherosclerosis2008201234535218472103
   PubMed Web of Science ®Google Scholar
• SasakiJIkedaYYamamotoKEffect of NK-104 (Pitavastatin) on Serum Lipids in Patients with Hypertriglyceridemia – Double-Blind, Cross-Over Placebo Controlled Study – [in Japanese]J Clin Therap Med2001176807827
   Google Scholar
• SoneHTakahashiAShimanoHHMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetesLife Sci200271202403241212231401
   PubMed Web of Science ®Google Scholar
• KoshiyamaHTaniguchiATanakaKKansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatarsJ Atheroscler Thromb200815634535019075492
   PubMed Web of Science ®Google Scholar
• NozueTMichishitaIItoYEffects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemiaJ Atheroscler Thromb200815314615318603821
   PubMed Web of Science ®Google Scholar
• TakashimaHOzakiYYasukawaTImpact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaqueCirc J200771111678168417965484
   PubMed Web of Science ®Google Scholar
• NakamuraTObataJEKittaYRapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndromeJ Cardiovasc Pharmacol200851436537118427279
   PubMed Web of Science ®Google Scholar
• HiroTKimuraTMorimotoTEffect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study)J Am Coll Cardiol20095429330219608026
   PubMed Web of Science ®Google Scholar
• NozueTYamamotoSTohyamaSTreatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): rationale and designCirc J200973235235519110505
   PubMed Web of Science ®Google Scholar
• InamiNNomuraSShouzuAEffects of pitavastatin on adiponectin in patients with hyperlipidemiaPathophysiol Haemost Thromb20073611818332608
   PubMedGoogle Scholar
• SakabeKFukudaNFukudaYComparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial functionInt J Cardiol2008125113613817400311
   PubMed Web of Science ®Google Scholar
• AoyagiTNakamuraFTomaruTBeneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failureInt Heart J2008491495818360064
   PubMed Web of Science ®Google Scholar
• NakamuraTSugayaTKawagoeEffect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney diseaseAm J Nephrol2006261828616534182
   PubMed Web of Science ®Google Scholar
• MajimaTShimatsuAKomatsuYShort-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemiaIntern Med200746241967197318084118
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [web site on the Internet] United States: the US National Institute of Health; ClinicalTrials.gov identifier: NCT00301392: Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) [updated on 2007 Jan 19; cited on 2006 Mar 5] Available from: http://clinicaltrials.gov/ct2/
   Google Scholar
• TajimaSHMG-CoA Reductase Inhibitor LIVALO Tablet [in Japanese]HosodaSSasayamaSKitamuraSThe series of advanced medicine, No 28 Cardiac Diseases “The frontier of diagnosis and treatment of cardiac diseases”TokyoResearch Center for Advanced Medical Technology2004343348
   Google Scholar
• KawashiriMANoharaATadaHComparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover studyClin Pharmacol Ther200883573173917957184
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• SabatineMSWiviottSDMorrowDAHighi-Dose Atorvastatin Associated with Glycemic Control: A PROVE-IT TIMI 22 SubstudyCirculation2004110Suppl IS834
   Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• KawaiTTokuiMFunaeOEfficacy of pitavastatin, a new HMG-CoA reductase Inhibitor, on lipid and glucose metabolism in patients with type 2 diabetesDiabetes Care200528122980298116306567
   PubMed Web of Science ®Google Scholar
• YamakawaTTakanoTTanakaSInfluence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitusJ Atheroscler Thromb200815526927518981652
   PubMedGoogle Scholar
• NakataMNagasakaSKusakaIEffects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic controlDiabetologia20064981881189216685502
   PubMed Web of Science ®Google Scholar
• KuriharaYDouzonoTKawakitaKA large-scale, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet) – drug use investigation. [in Japanese]Jpn Pharmacol Ther200751940
   Google Scholar
• KomanoNMasakiMKawaiHThe safety and efficacy in post-marketing surveys of atorvastatin. [in Japanese]Prog Med2005251131142
   Google Scholar
• YoshidaSCrestor: Safety and efficacy in clinical esperience investigation. [in Japanese]Prog Med200727511591189
   Google Scholar
• KuriharaYDouzonoTKawakitaKA large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet) – LIVALO Effectiveness and Safety (LIVES) StudyJpn Pharmacol Ther2008368709731
   Google Scholar